D-1492-2020 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-1492-2020 was initiated by Teva Pharmaceuticals USA on Jul 14, 2020 and is designated Class II. Reason for recall: Labeling: Incorrect or Missing Lot and/or Exp date on the individual transdermal pouches but not in the carton. The recall status is terminated (terminated Jul 7, 2021). Affected quantity: 28,596 cartons.

Recall details

Product Type
Drugs
Report Date
Aug 19, 2020
Initiation Date
Jul 14, 2020
Termination Date
Jul 7, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
28,596 cartons

Product description

Lidocaine Patch 5%, packaged in 30-count cartons, Rx only, Manufactured by: Actavis Laboratories UT, Inc., Salt Lake City, UT 84108, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 0591-3525-30

Reason for recall

Labeling: Incorrect or Missing Lot and/or Exp date on the individual transdermal pouches but not in the carton.

Distribution pattern

Nationwide United States

Code information

Carton Lot # 1383513B, Patch Lot # 1383513, Exp date 03/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1492-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1492-2020. Report a data issue: hello@regdatalab.com.